Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Radio-frequency Identification (RFID) Osteoporosis Pilot Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03385941
Recruitment Status : Not yet recruiting
First Posted : December 29, 2017
Last Update Posted : January 26, 2018
Sponsor:
Collaborator:
Massachusetts General Hospital
Information provided by (Responsible Party):
Neva Electromagnetics, LLC

Brief Summary:

This examines in-vivo microwave sensing to measure a radio- frequency signal propagating through the wrist and, based on this information, establish a correlation of measured parameters with the integral bone density. This radio- frequency device is designed to obtain an integral estimate of bone density (osteoporotic vs normal).

The measurements can be done in three ways. The first method (Method 1) utilizes Received Signal Strength (RSS) of an RFID tag array at 915 megahertz located on the top of the wrist. The transmitting antenna located on the bottom of the wrist is connected to an RFID reader. In that way, the signal travels twice across the wrist: from the reader to the tag and vice versa.

The second method (Method 2) is to use only one transmitting antenna, connect the transmitting antenna to a portable Network Analyzer and measure the reflection coefficient, S11, of the antenna itself. This method does not imply that the entire signal will travel back and forth through the wrist, although its significant portion will. This method is, however, broadband and allows us to measure antenna resonances, which are very sensitive to the wrist composition.

The third method (Method 3) is to use both transmitting and receiving antennas, connect the antennas to a portable KeySight Network Analyzer and measure the transmission coefficient, S21, of the antenna pair. This method implies that the entire signal will travel through the wrist once. This method is also broadband and allows us to measure decay of the radio-signal in the wrist over a band of frequencies.

The two last methods could be combined together.


Condition or disease
Age-Related Bone Loss Bone Loss, Age Related

Layout table for study information
Study Type : Observational
Estimated Enrollment : 24 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: RFID Osteoporosis Pilot Study
Estimated Study Start Date : January 31, 2018
Estimated Primary Completion Date : September 1, 2018
Estimated Study Completion Date : December 1, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoporosis

Group/Cohort
Osteoporotic
Femal, 50-80 years of age with established diagnosis of osteoporosis, based on prior DXA scan with T-score <-2.0 at any site and/or history of fragility fracture
Non-osteoporotic
Female, 27-40 years of age, no established history of osteoporosis



Primary Outcome Measures :
  1. Osteoporosis Screening through the use of a novel On-Body Passive Radio Frequency Identification (RFID) Array and corresponding test bed to include a receiving antenna. [ Time Frame: Data from the testing will be available in near real-time and will be collated and reported on within 1 week of the assessment ]
    A measurement will be performed to assess if a given patient is or is not at risk of osteoporosis. The measurement is based on the received signal strength or power received from the RFID tag.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   27 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
We are interested in a population comprised of female patients with and without osteoporosis.
Criteria

Inclusion Criteria:

In osteoporotic patients:

  • 50-80 years of age
  • Established diagnosis of osteoporosis, based on prior dual energy x-ray absorptiometry (DXA) scan with T-score <-2.0 at any site and/or history of fragility fracture

In healthy controls:

  • 27-40 years of age
  • Female

Exclusion Criteria:

In osteoporotic patients:

  • Current or recent (within 2 years) use of osteoporosis medications including bisphosphonates, hormone replacement therapy, selective estrogen receptor modulators, teriparatide, denosumab, calcitonin, or strontium
  • Pregnancy or breastfeeding within the past 2 years
  • Any medical or psychiatric condition or situation that would compromise subject safety, informed consent/assent, or data quality

In healthy controls:

  • History of significant cardiac, renal, pulmonary, hepatic, or malignant disease, or current alcohol or illicit drug abuse
  • Current diagnoses known to effect bone metabolism, including cystic fibrosis, diabetes, osteoporosis, amenorrhea >3 months (in menstruating women who are not taking oral contraceptives or have an IUD), hyperthyroidism, hyperparathyroidism, Paget's disease, kidney stones, chronic inflammatory diseases, malabsorptive disorders, malnutrition or eating disorder, endocrine disorders (growth disorder, Cushing syndrome), prolonged immobility, and skeletal dysplasias
  • History one or more pathologic fracture, or greater than four total lifetime non-digital, non-facial fractures
  • Cumulative lifetime use of oral glucocorticoids for greater than 2 months
  • Current or previous use of medications known to affect bone metabolism including hormone replacement therapy, anti-estrogens, bisphosphonates, calcitonin, lithium, suppressive doses of levothyroxine, or anticonvulsants.
  • Pregnancy or breastfeeding within the past 2 years
  • BMI less than 18.5 or greater than 30 kg/m2.
  • Any medical or psychiatric condition or situation that would compromise subject safety, informed consent/assent, or data quality

Layout table for additonal information
Responsible Party: Neva Electromagnetics, LLC
ClinicalTrials.gov Identifier: NCT03385941     History of Changes
Other Study ID Numbers: 2017P001452
First Posted: December 29, 2017    Key Record Dates
Last Update Posted: January 26, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoporosis
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases